Phathom Pharmaceuticals (PHAT) Cash from Operations (2018 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Cash from Operations of 1930000.0 for Q2 2026, up 96.92% year-over-year from 980077.15 in Q2 2025, and up 87.67% quarter-over-quarter from 15647000.0 in Q1 2026.
Powered by 
Analysis
Phathom Pharmaceuticals (PHAT) Cash from Operations (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Cash from Operations for 9 consecutive years, with 1930000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Operations rose 96.92% year-over-year to 1930000.0; the TTM figure through Jun 2026 stood at 36693000.0 (up 86.64% YoY), while the FY2025 annual figure was 166775000.0, up 37.48% from the prior year.
- Cash from Operations rose to 1930000.0 in Q2 2026 per PHAT's latest filing, from 15647000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 1930000.0 in Q2 2026 and bottomed at 84930000.0 in Q1 2025.
- Historically, Cash from Operations has averaged 40846222.22 across 5 years, with a median of 40355000.0 in 2022.
- Annual changes were most pronounced in 2024 — Cash from Operations plunged 218.56% — and 2026, when it jumped 96.92%.
- Phathom Pharmaceuticals' Cash from Operations stood at 41041000.0 in 2022, then fell by 6.72% to 43797000.0 in 2023, then sank by 44.89% to 63456000.0 in 2024, then soared by 92.12% to 5001000.0 in 2025, then surged by 61.41% to 1930000.0 in 2026.
- Business Quant data shows PHAT's Cash from Operations at 1930000.0 in Q2 2026, 15647000.0 in Q1 2026, and 5001000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Phathom Pharmaceuticals | 796.85 Mn | 611.51 Mn | 59.18 Mn | -1.93 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.93 Mn |
| Mar 31, 2026 | -15.65 Mn |
| Dec 31, 2025 | -5.00 Mn |
| Sep 30, 2025 | -14.12 Mn |
| Jun 30, 2025 | -62.73 Mn |
| Mar 31, 2025 | -84.93 Mn |
| Dec 31, 2024 | -63.46 Mn |
| Sep 30, 2024 | -63.57 Mn |
| Jun 30, 2024 | -70.72 Mn |
| Mar 31, 2024 | -69.02 Mn |
| Dec 31, 2023 | -43.80 Mn |
| Sep 30, 2023 | -31.91 Mn |
| Jun 30, 2023 | -22.20 Mn |
| Mar 31, 2023 | -39.67 Mn |
| Dec 31, 2022 | -41.04 Mn |
| Sep 30, 2022 | -35.02 Mn |
| Jun 30, 2022 | -25.72 Mn |
| Mar 31, 2022 | -44.76 Mn |
| Dec 31, 2021 | -41.26 Mn |
| Sep 30, 2021 | -29.07 Mn |